Iterum Therapeutics plc (id:6128 ITRM)
1.74 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 9:27:59 AM)
Exchange closed, opens in 1 minute
-2.25 USD (-2.25%)
-4.92 USD (-4.92%)
25.18 USD (25.18%)
51.30 USD (51.30%)
-8.90 USD (-8.90%)
-97.48 USD (-97.48%)
-99.09 USD (-99.09%)
About Iterum Therapeutics plc
Market Capitalization 48.70M
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Headquarters (address) |
Fitzwilliam Court Dublin D02 YW24 Ireland |
| Phone | 353 1 669 4820 |
| Website | https://www.iterumtx.com |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ITRM |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.00 - 3.02 |
| Market Capitalization | 48.70M |
| P/E trailing | 3.00 |
| P/E forward | -2.68 |
| Price/Book | -3.03 |
| Beta | 2.25 |
| EPS | -1.76 |
| EPS Ireland (ID:161, base:52) | 2.88 |